Glenmark launches fixed-dose triple therapy for COPD

Glenmark Pharmaceuticals has launched a groundbreaking nebulised triple therapy for COPD. This single, easy-to-use treatment combines three medicines to improve lung function and symptom control. It offers a new standard of care, especially for patients who find inhalers difficult. The therapy showed rapid improvement in lung function and breathlessness in a clinical study.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UGXfCxT
via IFTTT